Abstract
Background: While there is some literature on the cost of specific respiratory infections, much of the existing research focuses only on direct medical treatment costs and does not take into consideration workplace burden due to disability and absenteeism.
Objective: To evaluate the impact of lower respiratory tract infections (LRTIs) on the workplace, specifically regarding the economic burden from an employer’s perspective.
Design: Specific LRTI considered here were acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia. Data from medical, prescription drug and disability claims of a large, national company in the US were used. These data provide information on both the healthcare and work loss impacts of LRTI on this major self-insured employer. The annual per capita expenditures for persons with LRTI were determined for beneficiaries (including employees and dependants) of this employer by analysing all claims in 1997. Results were compared with those of a 10% random sample of beneficiaries in the employer’s overall beneficiary population.
Results: In 1997, total per person expenditures and total medical service utilisation were higher among beneficiaries with LRTI than among beneficiaries in the overall beneficiary population sample. Annual per capita employer expenditures for beneficiaries with LRTI totalled $US6116, compared with $US2368 (1997 values) for the average beneficiary in the overall beneficiary population sample. Employer payments for lost work time through disability and absenteeism accounted for 17% of these expenditures amongst beneficiaries with LRTI and for 35% amongst employees with LRTI.
Conclusions: Annual per capita expenditures for beneficiaries with LRTI were almost three times that of the average beneficiary. We conclude that it is important to consider work loss in analyses of the cost of LRTI.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Snow V, Mottur-Pilson C, Gonzales R, et al. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001 Mar 20; 134 (6): 518–20
Snow V, Lascher S, Mottur-Pilson C, et al. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001 Apr 3; 134 (7): 595–9
Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001 Apr 3; 134 (7): 600–20
Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000 May 22; 160 (10): 1399–408
Kollef M. The prevention of ventilator-associated pneumonia. N Engl J Med 1999 Feb 25; 340 (8): 627–34
Macfarlane IT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993 Feb 27; 341 (8844): 511–4
Fifty facts from the World Health Organization report 1997 [online]. Available from URL: http://www.who.int/whr/1997/factse.htm. [Accessed 2002 Jul 9]
Vital and health statistics: current estimates from the National Health review survey, 1996. Series 10, No. 200. Washington, D.C.: Centers for Disease Control and Prevention National Center for Health Statistics, 1999 Oct
International Conference on Acute Respiratory Infections 1997. Available from URL: http://www.neeph.anu.edu. [Accessed 2000 Aug 23]
Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and prognosis of severe community-acquired pneumoccocal respiratory infection. Intensive Care Med 1999 Feb; 25 (2): 198–206
Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000 May; 117 (5 Suppl. 2): 380S–5S
White CB, Foshee WS. Upper respiratory tract infections in adolescents. Adolesc Med 2000 Jun; 11 (2): 225–49
Niederman MS, McCombs IS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998 Jul–Aug; 20 (4): 820–37
Niederman MS, McCombs IS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999 Mar; 21 (3): 576–91
McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001 Sep–Oct; 4 (5): 370–5
Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000 Mar; 94 (3): 204–13
Ward MM, Javitz HS, Smith WM, et al. Direct medical costs of chronic obstructive pulmonary disease in USA. Respir Med 2000 Nov; 94 (11): 1123–9
Rutten van-Molken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics 2001; 19 Suppl. 2: 1–6
Garrelts JC, Herrington AM. Cost-effective treatment of lower respiratory tract infections. Pharmacoeconomics 1996 Jul; 10 (1): 36–58
Plosker GL, Foster RH, Benfield P. Cefotaxime: a pharmacoeconomic review of its use in the treatment of infections. Pharmacoeconomics 1998 Jan; 13 (1 Pt 1): 91–106
Grossman R. Cost-effective therapy for acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15 (1): 71–81
Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001 Feb; 14 (2): 52–9
Grossman RF. How do we achieve cost-effective options in lower respiratory tract infection therapy? Chest 1998 Mar; 113 (3 Suppl.): 205S–10S
Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999 Jul; 16 (1): 1–8
Burton WN, Conti DJ. Use of an integrated health data warehouse to measure the employer cots of five chronic disease states. Dis Manag Health Outcomes 1998; 2 (1): 17–26
Barnett A, Birnbaum HG, Cremieux PY, et al. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000 Nov; 6 (11): 1243–51
Employment characteristics of families in 1997. US Department of Labor Statistics. Available from URL: http://stats.bls.gov/newrels.htm [Accessed 2001 Jul 16]
Current population survey annual demographic survey. Available from URL: http://ferret.bls.census.gov/macro/031998/quint/15_000.htm [Accessed 2001 Jul 16]
Birnbaum H, Morley M, Greenberg PE, et al. Economic burden of pneumonia in an employed population. Arch Intern Med 2001 Dec 10–24; 161 (22): 2725–31
Destache CJ. Optimizing economic outcomes in acute exacerbations of chronic bronchitis. Pharmacotherapy 2002 Jan; 22 (1 Pt 2): 12S–7S
Acknowledgements
This research was funded by an unconditional grant from Aventis Pharmaceuticals, Bridgewater, NJ, USA. Dr Colice served as a consultant to Aventis Pharmaceuticals in other capacities. There are no other financial funding arrangements or potential conflicts of interest relevant to this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Birnbaum, H.G., Morley, M., Leong, S. et al. Lower Respiratory Tract Infections. Pharmacoeconomics 21, 749–759 (2003). https://doi.org/10.2165/00019053-200321100-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200321100-00006